Effect of pharmacological and non-pharmacological treatment on the expression of the Protein Tyrosine Phosphatase, Receptor Type D(PTPRD) and its relation with the restless legs syndrome in SHR rats.

• Grant number: 18/05245-5
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2018
• End date: October 31, 2020
• Field of knowledge: Health Sciences - Physical Education
• Principal Investigator: Andrea Maculano Esteves
• Grantee: Andrea Maculano Esteves
• Host Institution: Faculdade de Ciências Aplicadas (FCA). Universidade Estadual de Campinas (UNICAMP). Limeira , SP, Brazil
• Associated researchers: Adriana Souza Torsoni

Abstract

The Restless Leg Syndrome (RLS) is a common neurological sensorimotor disorder, manifested as an uncontrollable desire to move the body (legs) to relieve uncomfortable sensations. Recent studies show that variations in the PTPRD gene (Protein Tyrosine Phosphatase Receptor Type Delta) may increase the chance of developing this syndrome. The treatment for RLS may be pharmacological - medicines, or non-pharmacological - physical exercise (PE). This study aims to characterize the expression of PTPRD in SHR (Spontaneously Hypertensive Rats) animals and to verify the influence of pharmacological treatment (pramipexole - PPX), as well as non - pharmacological (physical exercise - PE) on the symptoms of RLS, sleep pattern and PTPRD expression. For this, SHR animals will be distributed in 5 groups: 1) Standard control (Wistar); 2) Control (SHR) 3) PE; 4) PPX; 5) PPX + PE; 6)A11 lesion. The intervention period will be 4 weeks. Treatment of the control and PE groups will consist of a saline vehicle. For the PPX and PPX + PE groups, the treatment will be performed at a dose of 0.1 mg / kg. All groups will receive saline / PPX daily. The PE will be performed on a treadmill, with 5 sessions per week lasting 1 hour each (moderate intensity). Electrocorticographic and electromyographic analyzes will be performed as well as the assessment of blood pressure. After the interventions, animals will be euthanized, followed by tissue extraction for the analysis of PTPRD, dopamine transporter, tyrosine hydroxylase, dopamine D2 receptor, iron, transferrin and ferritin by qPCR (Quantitative Polymerase Chain Reaction and Quantitative Polymerase Chain Reaction), Western Blotting and Elisa. The software that will be used for data analysis will be Statistica. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MORAIS, M.; FRANCO, B.; HOLANDA, A.; SIMINO, L.; MANCONI, M.; TORSONI, A.; ESTEVES, A.. Effect of pharmacological and non-pharmacological treatment on sleep pattern and serum iron levels in an animal model of Restless Legs syndrome. Journal of Sleep Research, v. 29, p. 1-pg., 2020-09-01. (18/05245-5)

MORAIS, MILCA ABDA; FRANCO, BEATRIZ SILVA; HOLANDA, ALESSANDRO SPENCER SOUZA; DE PAULA SIMINO, LAIS ANGELICA; VERAS, ALANA CAROLINA COSTA; TORSONI, MARCIO ALBERTO; MANCONI, MAURO; TORSONI, ADRIANA SOUZA; ESTEVES, ANDREA MACULANO. Protein tyrosine phosphatase receptor type delta (PTPRD) gene in an animal model of restless legs syndrome. Journal of Sleep Research, v. N/A, p. 10-pg., 2022-09-02. (18/05245-5)

MORAIS, MILCA A.; FRANCO, BEATRIZ; HOLANDA, ALESSANDRO S. S.; SIMINO, LAIS ANGELICA DE PAULA; MANCONI, MAURO; TORSONI, ADRIANA; ESTEVES, ANDREA M.. PTPRD as a candidate druggable target for therapies for restless legs syndrome?. Journal of Sleep Research, v. 30, n. 4, OCT 2020. (18/05245-5)